Eiger BioPharmaceuticals Inc

NASDAQ:EIGR   3:59:57 PM EDT
7.95
-0.20 (-2.45%)
Products

Eiger BioPharmaceuticals Inc Announces An Oral Poster Presentation Of Phase 2 Study Results Of Avexitide In Congenital Hyperinsulinism

Published: 06/28/2021 13:19 GMT
Eiger BioPharmaceuticals Inc (EIGR) - Eiger Biopharmaceuticals Inc - Announced an Oral Poster Presentation of Phase 2 Study Results of Avexitide in Congenital Hyperinsulinism (hi).
Eiger Biopharmaceuticals - Avexitide Significantly Reduced Gir When Evaluated Across Dose Levels (p=0.0087) With Dose-dependent Improvements Observed.
Eiger Biopharmaceuticals - Adverse Events Were Typically Mild in Severity & Transient, & There Were No Serious Adverse Events in Phase 2 Avexitide Study.